1 / 27

Electronic Fetal Monitoring: An Update

Electronic Fetal Monitoring: An Update. James Paul Ching Maganito, DO, MPH, MHA, CHES Obstetrics and Gynecology Yakima Valley Farm Workers Clinic Yakima Valley Memorial Hospital. Objective. Refamiliarize ourselves with the recent ACOG practice bulletin guidelines, July 2009

eichorn
Download Presentation

Electronic Fetal Monitoring: An Update

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Electronic Fetal Monitoring: An Update James Paul Ching Maganito, DO, MPH, MHA, CHES Obstetrics and Gynecology Yakima Valley Farm Workers Clinic Yakima Valley Memorial Hospital

  2. Objective • Refamiliarize ourselves with the recent ACOG practice bulletin guidelines, July 2009 • Reemphasize definition to apply to clinical practice and documentation

  3. Background • FHR monitoring • Original rationale – screening test for asphyxia to prevent neurologic damage / fetal death • Original research started in the 1960’s • Study done on term pregnancy noted fetal asphyxia of unknown origin in 63% of the research sample (1) (1) Low JA, et al. The prediction and preention of intrapartum fetal asphyxia in term pregnancies. Am J Obstet Gynecol 2001; 184: 724-30

  4. Guidelines for Nomenclature and Interpretation of Electronic Fetal Heart Rate Monitoring • 2008 • Eunice Kennedy Shriver National Institute of Child Health and Human Development • American College of Obstetricians and Gynecologist • Workshop focused on FHR monitoring • Three goals • To review and update the definitions for FHR pattern categorization from the prior workshop • To assess existing classification systems for interpreting specific FHR patterns and make recommendations about a system for use in the United States • To make recommendations for research priorities for EFM

  5. True or False • With regards to uterine contraction, the term hyperstimulation and hypercontractility is still used today and should be adopted and documented?

  6. Uterine Contractions • Definition • Uterine contractions are quantified as the number of contractions present in a 10 minute window, average over a 30 minute period • Documentation should include: frequency, duration, intensity, relaxation time • Terminologies • Normal: < 5 Ctx in 10min avg over 30min window • Tachysystole: > 5 Ctx in 10min avg over 30min window • Always qualified as to the presence or absence of associated FHR decelerations • Applies to both spontaneous and stimulated labor

  7. True or False? • FHR baseline should be document as a range in order to avoid any confusion and give the team a better idea of the characteristic of the baseline?

  8. Baseline • FHR rounded to increments of 5bpm during a 10min segment, for at least 2mins, excluding • Periodic or episodic changes • Periods of marked FHR variability • Segments of baseline that differ by more than 25bpm • Normal: 110-160bpm • Tachycardia: > 160 bpm • Bradycardia: < 110bpm

  9. True or False • Variability should be described and documented as “no,” “good,” or “severe” as well as in terms of short-term versus long-term variability?

  10. Baseline Variability • Absent: undetectable • Minimal: < 5bpm • Moderate: 6-25bpm • Marked: > 25 bpm

  11. Accelerations • Abrupt increase (onset to peak is < 30secs) • > 32 wk GA, > 15bpm above BL > 15secs but less than 2 mins from onset to return • < 32 wks, > 10bpm above BL > 10secs but less than 2mins from onset to return • Prolonged accelerations last 2mins or more but less than 10mins • > 10 mins is a baseline change

  12. True or False • Decelerations are described and documented as persistent, repetitive, or rare? • Decelerations should be described as: • Periodic: associated w/ uterine contractions • Episodic: no association w/ uterine contractions • Recurrent: repetitive

  13. Decelerations • Early • Gradual decrease, nadir = peak of ctx • Variable • Abrupt decrease, > 15 bpm lasting 15 secs but less than 2 mins • Late • Gradual decrease, nadir = after peak of ctx • Prolonged • > 15bpm, lasting > 2 mins but less than 10 mins • Sinusoidal • Smooth, sine wave, cycle frequency of 3-5 per min persisting 20mins or more

  14. Classification of FHR Tracing • Category I • Category II • Catergory III

  15. Classification of FHR Tracings • Category I • BL: 110-160bpm • BL FHR variability: moderate • Accelerations: present • Early Decels: present or absent • Late or variable decels: absent • Monitor Routinely • No Specific Actions required

  16. Classsification of FHR Tracing • Category II • BL: • Bradycardia not accompanied by absent variability • Tachycardia • BL Variability • Minimal or marked variability • Absent with no recurrent decels • Accelerations • Absence of induced acceleration after fetal stimulation • Periodic / Episodic decels • Recurrent variable decels • Prolonged decels • Recurrent later decels • Perform Ancillary Test to ensure fetal well being or intrauterine resuscitative measures may be used

  17. Classification of FHR Tracing • Category III • BL: Absent with recurrent late/variable decels or bradycardia • Sinusoidal pattern • Prompt evaluation • Depending on clinical scenario, expeditiously resolve abnormal FHR pattern by intrauterine resuscitative efforts • IF NOT resolved – delivery should be undertaken

  18. Guidelines for Review of Electronic FHR Monitoring • Pt w/o complications • First stage: q 30mins • Second stage: q 15mins • Pt w/ complications • First stage: q 15mins • Second stage: q 5mins

  19. Efficacy of FHR monitoring • INCREASED overall cesarean section delivery rate • INCREASED operative vaginal delivery – vacuum and forcep • Did NOT reduce cerebral palsy risk • False positive rate is > 99% in predicting cerebral palsy • Rationale: 70% of CP occurs before onset of labor & only 4% can be attributed to intrapartum events • Reduced risk of neonatal seizures

  20. Poor interobserver and intraobserver variability • The ACOG guidelines highlight a case in which four obstetricians examined 50 FHR tracings; they agreed in only 22% of the cases. Two months later, these four physicians reevaluated the same 50 FHR tracings, and they changed their interpretations on nearly one out of every five tracings. • Foreknowledge of neonatal outcome – alters the reviewer’s impressions of FHR tracings – thus not reliable.

  21. Medication Effects on FHR • Narcotics • 75mg meperidine (Demerol) = 10mg morphine = 0.1 fentanyl = 10mg nalbuphine (nubain) • Decrease variability, decrease frequency of accels • Butorphanol (Stadol) • Transient sinusoidal pattern • Corticosteroid • Betamethasone: decrease variability – returns to normal by fourth to 7th day post treatment • Dexamethasone: no change • MgSO4 • Decreased variability with early gestational age • Mg level did not affect variability • Terbutaline • Increase baseline FHR and incidence of fetal tachycardia

  22. Ancillary Test to Aid Management of Category II and III • Fetal Scalp Sampling • Consider with Category III – difficult b/c of decrease in physician experience, difficulty, processing sample • Allis Clamp Scalp Stimulation • Vibroacoustic Stimulation • Digital Scalp Stimulation

  23. Intrauterine Resuscitation • Discontinuation of labor stimulating agent • Cervical exam • Determine umbilical cord prolapse • Rapid cervical dilation • Descent of the fetal head • Change maternal position • Monitoring maternal blood pressure level (Hypotension) • If secondary to regional anesthetic, volume expansion or IV ephedrine or both • Assessment of pt for uterine tachysystole • Supplemental oxygen for indeterminate or abnormal patterns • There is no data on the efficacy or safety of this therapy • Tocolytic agent • If position and oxygenation does not change FHR pattern • Although tocolytic therapy appears to reduce the number of FHR abnormalities, there is insufficient evidence to recommend it. • Amnioinfusion • Recurrent variable decels • Decrease rate of decel, decrease hospitalization time of pt and newborn

  24. Conclusion • Baseline – multiple of 5 • Variability – Absent, Minimal, Moderate, Marked • Accels – no asphyxia • Decels: Early, Variable, Late – Periodic, Episodic, Recurrent (Recurrent periodic/episodic) • If in category II and III – physician should be present to evaluate the pt and fetus

  25. Lastly… • Computer vs “expert” human visualization, evaluation, and interpretation of electronic fetal heart tracing has been shown to have no statistical difference.

  26. Reference • GE: Electronic Fetal Heart Monitoring: Research Guidelines for Interpretation • ACOG Practice Bulletin. Intrapartum Fetal Heart Rate Monitoring: Nomenclature, Interpretation, and General Management Principles. Number 106, July 2009 • National Institute of Child Health and Human Development workshop report on electronic fetal monitoring: update on definitions, interpretation, and research guidelines. Obstet Gynecol 2008; 112:661-6

More Related